A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Inclusion Criteria:

• Histologically documented, locally advanced, recurrent, or metastatic incurablesolid tumors

• Participants with measurable disease according to RECIST v1.1 assessed by theinvestigator

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Life expectancy ≥12 weeks

• Adequate hematologic and end-organ function

• Confirmed presence of the RAS mutation(s)

Exclusion Criteria:

• Current participant or enrollment in another interventional clinical trial

• Known hypersensitivity or medical contraindication to any component of RO7673396formulation

• Refractory nausea and vomiting, malabsorption, external biliary shunt, orsignificant small bowel resection that would preclude adequate study treatmentabsorption

• Known and untreated, or active central nervous system (CNS) metastases

• Participants with chronic diarrhea, short bowel syndrome or significant uppergastrointestinal (GI) surgery including gastric resection, a history of inflammatorybowel disease

• Treatment with chemotherapy, immunotherapy, biologic therapy, or an investigationalagent as anti-cancer therapy within 4 weeks or five half-lives prior to initiationof study treatment

• Major surgical procedure within 28 days prior to initiation of study treatment, orincomplete recovery from surgery that would interfere with the determination ofsafety or efficacy of study treatment, or anticipation of need for a major surgicalprocedure during the study

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrentdrainage procedures

• Known clinically significant liver disease